Corrine Savill - Feb 17, 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Business Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Feb 17, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 05:57 PM
Previous filing
Jul 21, 2022
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +20.5K +13.7% $0.00 170K Feb 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +41K $0.00 41K Feb 17, 2023 Common Stock 41K $11.34 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney